Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “alcohol” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 117
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 117 pipeline programs matching "alcohol" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

117 results for “alcohol” Back to intelligence hub

Search results

Page 3 of 5
  1. Miricorilant

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    3 trials
  2. Miricorilant (Cohort A)

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial
  3. NN9500-4656

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial
  4. NN9500-7730

    NovoThirteen

    alcohol-related liver disease

    phase 2 small molecule active

    1 trial
  5. Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Dependence

    phase 2 small molecule completed

    1 trial
  6. Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol-Related Disorders

    phase 2 small molecule completed

    3 trials
  7. Namodenoson

    Can-Fite BioPharma

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule active

    1 trial
  8. Namodenoson, Matching placebo for namodenoson

    Can-Fite BioPharma

    Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

    phase 2 small molecule active

    1 trial
  9. ORMD-0801 QD

    ORAMED PHARMACEUTICALS INC.

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial
  10. Oral Insulin

    ORAMED PHARMACEUTICALS INC.

    Non-Alcoholic Steatohepatitis (NASH)

    phase 2 mab completed

    1 trial
  11. Oxytocin

    United Therapeutics Europe Ltd

    Alcohol Use Disorder

    phase 2 small molecule completed

    1 trial
  12. PF-05190457

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholism

    phase 2 small molecule terminated

    1 trial
  13. Placebo

    Lacuna Pharma Pty Ltd

    Severe Alcohol-Associated Hepatitis

    phase 2 small molecule active

    1 trial
  14. Rencofilstat

    Hepion Pharmaceuticals

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial
  15. SHP626

    Mirum Pharmaceuticals International B.V.

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    3 trials
  16. Sertraline

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholism

    phase 2 small molecule terminated

    1 trial
  17. TEV-45478

    Teva Pharma GmbH

    Nonalcoholic Steatohepatitis

    phase 2 small molecule terminated

    1 trial
  18. TVB-2640

    Sagimet Biosciences

    Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial
  19. VK2809

    Viking Therapeutics

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial
  20. Varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Dependence

    phase 2 small molecule completed

    1 trial
  21. Vitamin E

    NORTHWEST BIOTHERAPEUTICS INC

    Nonalcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial
  22. Zonisamide

    United Therapeutics Europe Ltd

    Alcohol Dependence

    phase 2 small molecule completed

    1 trial
  23. varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholism

    phase 2 small molecule completed

    1 trial
  24. A study to compare two different aramchol formulations in healthy volunteers.

    Galmed Pharmaceuticals

    Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Primary sclerosing cholangitis

    phase 1 other active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.